Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 7Lymphoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Recurrence 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Solid Tumors 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Bortezomib 9Brentuximab Vedotin 7Filgrastim 6Vorinostat 5Doxorubicin 5tanespimycin 4Whole-Body Irradiation 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Paclitaxel 4Gemcitabine 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Carboplatin 4Biopsy 4sargramostim 3romidepsin 3fludarabine 3Topotecan 3Rifampin 3Prednisone 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Leucovorin 3Lenalidomide 3Irinotecan 3Fluorouracil 3Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large-Cell, Anaplastic × Ketoconazole × Clear all
NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡